The Therapeutic Goods Administration (TGA), the regulatory body for therapeutic goods in Australia, has prohibited sale, supply and use of DMAA (1,3-dimethylamylamine), an ingredient used in some sports supplements.
The TGA noted that it made the decision in response to safety concerns about the abuse of DMAA and following advice from the Advisory Committee on Medicines Scheduling (ACMS) and public consultation.
After this decision, state and territory governments will implement any necessary changes to legislation, while state and territory authorities are responsible for enforcing these laws.
DMAA acts as a stimulant and is used in pre-workout sports supplements and party pills to offer an adrenaline-like high. It has been linked with various adverse health effects including high blood pressure, headaches, vomiting, cerebral haemorrhage, stroke and death.
People, who have consumed these products and concerned about any health risks, have been advised to consult their doctors.
New Zealand banned DMAA from all products in April 2012 after reports of adverse effects.
